ID   U-CH11
AC   CVCL_1D67
SY   UCH11
DR   ATCC; CRL-3302
DR   cancercelllines; CVCL_1D67
DR   GEO; GSM1673857
DR   GEO; GSM1673858
DR   Wikidata; Q54973613
RX   PubMed=26183925;
RX   PubMed=28515451;
WW   https://www.chordomafoundation.org/researchers/disease-models/u-ch11/
CC   Population: Caucasian.
CC   Doubling time: 10 days (PubMed=26183925); 15 days (Chordoma Foundation).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Unspecified (PubMed=28515451).
CC   Omics: Transcriptome analysis by microarray.
CC   Discontinued: ATCC; CRL-3302; true.
CC   Derived from site: In situ; Bone, sacrum; UBERON=UBERON_0003690.
ST   Source(s): PubMed=26183925
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 14
ST   D16S539: 9,11
ST   D18S51: 14
ST   D3S1358: 15
ST   D7S820: 9,10
ST   D8S1179: 13,16
ST   Penta D: 9,12
ST   Penta E: 7,14
ST   TH01: 6,9.3
ST   TPOX: 8
DI   NCIt; C129927; Sacral chordoma
DI   ORDO; Orphanet_178; Chordoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_VR46 ! U-CH11R
SX   Male
AG   71Y
CA   Cancer cell line
DT   Created: 08-07-15; Last updated: 19-12-24; Version: 16
//
RX   PubMed=26183925; DOI=10.1158/0008-5472.CAN-14-3270;
RA   von Witzleben A., Goerttler L.T., Marienfeld R., Barth H., Lechel A.,
RA   Mellert K., Bohm M., Kornmann M., Mayer-Steinacker R., von Baer A.,
RA   Schultheiss M., Flanagan A.M., Moller P., Bruderlein S., Barth T.F.E.;
RT   "Preclinical characterization of novel chordoma cell systems and their
RT   targeting by pharmocological inhibitors of the CDK4/6 cell-cycle
RT   pathway.";
RL   Cancer Res. 75:3823-3831(2015).
//
RX   PubMed=28515451; DOI=10.1038/s41598-017-02174-5; PMCID=PMC5435709;
RA   Jager D., Barth T.F.E., Bruderlein S., Scheuerle A., Rinner B.,
RA   von Witzleben A., Lechel A., Meyer P., Mayer-Steinacker R., von Baer A.,
RA   Schultheiss M., Wirtz C.R., Moller P., Mellert K.;
RT   "HOXA7, HOXA9, and HOXA10 are differentially expressed in clival and
RT   sacral chordomas.";
RL   Sci. Rep. 7:2032-2032(2017).
//